Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention

Curr Atheroscler Rep. 2020 Oct 6;22(12):76. doi: 10.1007/s11883-020-00890-4.

Abstract

Purpose of review: Patients diagnosed with coronary artery disease are at a high risk of subsequent cardiovascular events; therefore, secondary prevention in the form of therapeutic lifestyle changes, and drug therapies is vital. This article aims to review potential application of intra-coronary imaging for the evaluation of plaque modifications, induced by medications for secondary prevention for CAD.

Recent findings: Intra-coronary imaging provides detailed information on the atherosclerotic plaque which is the primary pathological substrate for the recurrent ischemic cardiovascular events. These modalities can detect features associated with high risk and allow serial in vivo imaging of lesions. Therefore, intravascular imaging tools have been used in landmark studies and played a role in improving our understanding of the disease processes. Changes in size and plaque composition over time can be evaluated by these tools and may help understanding the impact of a treatment. Moreover, surrogate imaging end points can be used when testing new drugs for secondary prevention.

Keywords: Coronary artery disease; Coronary atherosclerosis; Intra-coronary imaging; Secondary prevention; Vulnerable plaque.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Blood Component Removal / methods
  • Cholesterol, HDL / blood
  • Coronary Artery Disease / complications
  • Coronary Artery Disease / diagnostic imaging*
  • Coronary Artery Disease / drug therapy*
  • Coronary Artery Disease / prevention & control
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • PCSK9 Inhibitors*
  • Plaque, Atherosclerotic / complications
  • Plaque, Atherosclerotic / diagnostic imaging*
  • Plaque, Atherosclerotic / drug therapy*
  • Plaque, Atherosclerotic / prevention & control
  • Protease Inhibitors / therapeutic use*
  • Secondary Prevention*
  • Ultrasonography, Interventional / methods*

Substances

  • Cholesterol, HDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • PCSK9 Inhibitors
  • Protease Inhibitors
  • PCSK9 protein, human